Forbes December 12, 2023
Ever since the passing of the Inflation Reduction Act (IRA), the impact of this legislation on the discovery and development of new medicines has been debated. Now, a white paper from ATI Advisory has provided a snapshot of the early impact of the IRA on the biopharma industry. Entitled “Pharmaceutical Innovation and the Inflation Reduction Act: What can we learn from the first half of 2023,” this policy brief examines whether “the IRA has had immediate impacts on drug development.”
ATI Advisory was pretty thorough in compiling data for the first six months of 2023 using published information on 18 leading companies with respect to R&D budget changes, discontinuation of development candidates, and even M&A activity. Essentially, ATI Advisory shows...
Today's Sponsors
Today's Sponsor